Search results
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
Remdesiwir prawdopodobnie zmniejsza ryzyko zaostrzenia się choroby i hospitalizacji, nie można jednak jednoznacznie stwierdzić, czy wpływa na poprawę stanu zdrowia (np. złagodzenie objawów). • W przyszłych badaniach należy sprawdzić wpływ remdesiwiru na przebieg COVID-19 w różnych podgrupach (np. u osób o lżejszym lub ...
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized...
30 lip 2020 · Remdesivir probably has no important effect on need for invasive mechanical ventilation. Remdesivir may have little or no effect on hospital length of stay. Understanding the recommendation: Most patients with severe covid-19 would likely choose treatment with remdesivir given the potential reduction in time to clinical improvement. However ...
21 maj 2022 · Despite 2 years having passed since the start of the COVID-19 pandemic, there is still intense debate about the best therapeutic strategy for patients with COVID-19. Multiple randomised studies have evaluated the efficacy of different antiviral,1,2 anti-inflammatory, and antithrombotic treatments.
30 lip 2020 · Remdesivir may reduce time to clinical improvement (mean difference 3.04 days fewer (0.89 to 5.19 days fewer), mean in supportive care group 19 days, mean in remdesivir group 16 days); this result also has low certainty due to imprecision and indirectness.
21 sty 2021 · Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021 Nov;190 (4):1637-1638. doi: 10.1007/s11845-020-02482-2. Epub 2021 Jan 12. Authors. Antonio Vitiello 1 , Francesco Ferrara 2 , Raffaele La Porta 3. Affiliations.
